In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Xenical OTC Actual Use Trial Shows Dose Compliance, Glaxo Says

This article was originally published in The Tan Sheet

Executive Summary

Only a single consumer reported exceeding Xenical dose guidelines in a 237-person actual use trial of the weight-loss drug, Glaxo researchers report

You may also be interested in...



Xenical Study Supports Proposed Nonprescription Dose, Glaxo Says

The "behavior modification" effect ofXenical adverse events could help allay concerns that OTC availability would lead to people using orlistat without making appropriate adjustments to their diets, according to the principal investigator of a study on the drug

Judge Orders FDA, Food Safety Group To Set FSMA Implementation Date

FDA’s delays in implementing the Food Safety Modernization Act violated FSMA and the Administrative Procedures Act, a federal court finds in an April 22 order. The agency must meet with plaintiff Center for Food Safety to agree on new implementation deadlines by May 20.

Judge Orders FDA, Food Safety Group To Set FSMA Implementation Date

FDA’s delays in implementing the Food Safety Modernization Act violated FSMA and the Administrative Procedures Act, a federal court finds in an April 22 order. The agency must meet with plaintiff Center for Food Safety to agree on new implementation deadlines by May 20.

Topics

UsernamePublicRestriction

Register

PS098789

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel